2.50
Hdl Handle:
http://hdl.handle.net/10541/82002
Title:
Clinical use of pegvisomant for the treatment of acromegaly.
Authors:
Drake, William M; Trainer, Peter J
Abstract:
Understanding the mechanisms by which growth hormone (GH) interacts with its receptor has led to the design of compounds that function as GH receptor antagonists. One such compound has been conjugated to polyethylene glycol (PEG) to produce a drug, pegvisomant, which has been extensively investigated as a treatment for acromegaly. It was recently approved for clinical use in the US and will shortly be available on prescription in Europe. Studies have shown that the drug is able to normalize circulating levels of insulin-like growth factor-1 (IGF-1), the principal mediator of GH action, in 97% of patients with active acromegaly, as well as improve the symptoms and signs associated with GH excess. Serum IGF-1 levels have been used as the chief marker of efficacy of treatment with pegvisomant. The drug is able to achieve biochemical control in patients wholly or partially resistant to somatostatin analogs. Preliminary data suggests that pegvisomant may be a particularly suitable choice of medical therapy for patients with acromegaly and coexistent diabetes mellitus.
Affiliation:
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Citation:
Clinical use of pegvisomant for the treatment of acromegaly. 2003, 2 (6):369-74 Treat Endocrinol
Journal:
Treatments in Endocrinology
Issue Date:
2003
URI:
http://hdl.handle.net/10541/82002
PubMed ID:
15981941
Type:
Article
Language:
en
ISSN:
1175-6349
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDrake, William M-
dc.contributor.authorTrainer, Peter J-
dc.date.accessioned2009-09-22T11:37:03Z-
dc.date.available2009-09-22T11:37:03Z-
dc.date.issued2003-
dc.identifier.citationClinical use of pegvisomant for the treatment of acromegaly. 2003, 2 (6):369-74 Treat Endocrinolen
dc.identifier.issn1175-6349-
dc.identifier.pmid15981941-
dc.identifier.urihttp://hdl.handle.net/10541/82002-
dc.description.abstractUnderstanding the mechanisms by which growth hormone (GH) interacts with its receptor has led to the design of compounds that function as GH receptor antagonists. One such compound has been conjugated to polyethylene glycol (PEG) to produce a drug, pegvisomant, which has been extensively investigated as a treatment for acromegaly. It was recently approved for clinical use in the US and will shortly be available on prescription in Europe. Studies have shown that the drug is able to normalize circulating levels of insulin-like growth factor-1 (IGF-1), the principal mediator of GH action, in 97% of patients with active acromegaly, as well as improve the symptoms and signs associated with GH excess. Serum IGF-1 levels have been used as the chief marker of efficacy of treatment with pegvisomant. The drug is able to achieve biochemical control in patients wholly or partially resistant to somatostatin analogs. Preliminary data suggests that pegvisomant may be a particularly suitable choice of medical therapy for patients with acromegaly and coexistent diabetes mellitus.en
dc.language.isoenen
dc.subject.meshAcromegaly-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin Resistance-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshReceptors, Somatotropin-
dc.subject.meshSeverity of Illness Index-
dc.titleClinical use of pegvisomant for the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, St Bartholomew's Hospital, London, UK.en
dc.identifier.journalTreatments in Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.